Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease characterised by profound barrier dysfunction (primarily filaggrin deficiency), type 2 inflammation with Th2 immune dominance, intense pruritus, and recurrent cutaneous infections. It represents the initial manifestation of the atopic march, establishing systemic immune dysregulation that typically progresses to food allergies, asthma, and allergic rhinitis.
Imagine your skin as a brick wall protecting your home. Each brick is a skin cell (keratinocyte), and the mortar holding them together is filaggrin β a protein that breaks down into natural moisturising factors and maintains the barrier's integrity. In atopic dermatitis, you're born with faulty mortar (filaggrin mutations) or something keeps destroying the mortar you make (IL-4 and IL-13 suppress filaggrin production). Without proper mortar, the wall develops cracks. Rain gets through (water evaporates out causing dryness), but worse β burglars can now enter through the cracks. These "burglars" are allergens like peanut proteins, dust mite particles, or pollen. Because they're entering through the wall instead of the front door (oral route), your home security system (immune system) treats them as dangerous intruders requiring a full SWAT team response (Th2 activation, IgE production). The SWAT team deploys chemical irritants (IL-31, histamine) that make you scratch, which damages the wall further. Meanwhile, opportunistic squatters (Staphylococcus aureus) move into the cracks, spray-painting toxins everywhere and calling more SWAT teams. The system becomes a vicious cycle: damaged wall β allergen entry β immune alarm β scratching β more wall damage. The critical insight: the first contact point determines everything. If peanut protein enters through your damaged skin wall, you become allergic. If it had entered through the "proper entrance" (eating it with a healthy gut), your immune system would have welcomed it as a guest, not an intruder.
graph TD
A["Filaggrin deficiency<br/>FLG mutation or IL-4/IL-13 suppression"] --> B[Impaired skin barrier]
B --> C["Increased TEWL<br/>transepidermal water loss"]
B --> D["Allergen penetration<br/>through damaged stratum corneum"]
D --> E["Langerhans cell activation<br/>antigen presentation"]
E --> F["Th2 differentiation<br/>IL-4, IL-13 production"]
F --> G["IgE class switching<br/>B cell activation"]
F --> H["IL-31 production<br/>itch neurons"]
F --> I["Further filaggrin suppression<br/>vicious cycle"]
H --> J[Scratching behavior]
J --> B
F --> K["Reduced antimicrobial peptides<br/>defensins, cathelicidin"]
K --> L["S. aureus colonization >90%"]
L --> M["Superantigen production<br/>SEB, TSST-1"]
M --> F
L --> N["Alpha-toxin damage<br/>keratinocyte death"]
N --> B
G --> O["Systemic sensitization<br/>atopic march initiation"]
Primary barrier dysfunction cascade:
-
Filaggrin deficiency (FLG gene loss-of-function mutations in ~60% of moderate-to-severe AD; R501X and 2282del4 most common in European populations) β reduced natural moisturising factors (NMF: urocanic acid, pyrrolidone carboxylic acid) β elevated skin pH (from 5.5 to >6.0) β increased serine protease activity β degradation of corneodesmosomes β impaired stratum corneum cohesion
-
Cytokine feedback loop: IL-4 and IL-13 (from Th2 cells and ILC2s) bind IL-4RΞ± β STAT6 phosphorylation β suppression of FLG gene transcription β further barrier compromise β amplified allergen entry
Type 2 immune activation:
-
Allergen entry through damaged barrier β processed by epidermal Langerhans cells and dermal dendritic cells β migration to draining lymph nodes β presentation to naΓ―ve T cells with MHC-II
-
Th2 differentiation: Dendritic cells produce IL-4 and TSLP β STAT6 activation β GATA3 transcription factor β Th2 phenotype β production of IL-4, IL-5, IL-13, IL-31
-
IgE production: IL-4 β B cell class-switch recombination β IgE synthesis β binds to FcΞ΅RI on mast cells and basophils β primed for degranulation upon allergen re-exposure
-
Pruritogenic cascade: IL-31 (primary itch cytokine) β binds IL-31RA/OSMR heterodimer on sensory neurons β JAK-STAT activation β itch signal β scratching β mechanical barrier damage (Koebner phenomenon)
Microbial dysbiosis:
-
Antimicrobial peptide deficiency: IL-4/IL-13 suppress LL-37 (cathelicidin) and Ξ²-defensin production β reduced killing of S. aureus β colonisation exceeds 90% (vs. 5% in healthy skin)
-
S. aureus pathogenicity: Produces Ξ±-toxin (Ξ±-hemolysin) β pore formation in keratinocytes β cell lysis and barrier destruction; secretes superantigens (SEB, SEA, TSST-1) β polyclonal T cell activation β massive cytokine release β inflammation amplification
-
Skin microbiome collapse: Reduced diversity (loss of Staphylococcus epidermidis, Cutibacterium, Corynebacterium) β dominance of pathogenic S. aureus strains β biofilm formation β chronic inflammation
Dual allergen exposure hypothesis:
-
Cutaneous sensitisation route: First allergen contact through damaged skin (e.g., peanut dust on eczematous skin) β Th2 priming β IgE production β systemic food allergy (6-fold increased risk)
-
Oral tolerance failure: In AD infants, gut barrier is often compromised β allergens enter systemically rather than being tolerised by gut-associated lymphoid tissue β amplifies atopic march progression
Position in atopic march cascade:
Atopic dermatitis is not an isolated dermatological condition but the entry lesion for lifelong atopic disease. The "dual allergen exposure hypothesis" explains mechanistically why AD in infancy predicts subsequent food allergies (develops in 30-40% of AD patients), asthma (50% risk), and allergic rhinitis (70% risk). The damaged skin barrier allows allergen sensitisation to occur through the "wrong route" β cutaneously rather than orally β establishing type 2 immune memory that manifests systemically.
cPNI intervention framework:
Treatment must address three concurrent systems:
-
Barrier restoration (skin ecosystem):
- L-histidine supplementation (1-2g/day) β filaggrin synthesis support (histidine is rate-limiting amino acid for filaggrin production)
- Topical ceramides (particularly ceramide 1, 3, 6-II) β lipid bilayer repair
- Emollient therapy (twice-daily minimum) β reduced TEWL, physical barrier support
- pH optimisation β acidic washes (pH 5.5) restore protease balance
-
Immune rebalancing (Th1/Th2 ratio):
- Vitamin D (target 40-60 ng/mL) β enhances antimicrobial peptide production, modulates Th2 responses
- Zinc (25-50mg elemental zinc) β supports Th1 function, required for metalloproteinases
- Omega-3 fatty acids (EPA/DHA 2-3g/day) β shift from pro-inflammatory eicosanoids to resolvins
- Early oral allergen introduction (in infants 4-6 months) β promotes oral tolerance before skin sensitisation occurs (LEAP trial evidence)
-
Gut-skin axis optimisation:
- Gut barrier repair β L-glutamine, zinc-carnosine, probiotics (Lactobacillus rhamnosus GG shows efficacy in AD prevention)
- Microbiome restoration β diverse fibre intake, fermented foods β supports production of SCFAs that regulate Treg function
- Reduction of gut-derived endotoxin β lower systemic LPS reduces inflammasome activation and type 2 skewing
Clinical biomarkers and thresholds:
- Total serum IgE typically >200 IU/mL (often >1000 IU/mL in severe AD)
- Eosinophil count elevated (>500 cells/ΞΌL indicates type 2 inflammation)
- TEWL (transepidermal water loss) >25 g/mΒ²/h indicates severe barrier dysfunction (normal <10 g/mΒ²/h)
- Vitamin D deficiency (<20 ng/mL) correlates with AD severity and infection risk
- IL-31 levels correlate with itch intensity (emerging therapeutic target)
Evolutionary mismatch considerations:
The atopic march represents a dysregulated immune education phenomenon. In evolutionary environments with high pathogen exposure, early microbial contact through a healthy gut barrier trained balanced Th1/Th2 responses. Modern hygiene, Caesarean births, antibiotic exposure, and delayed allergen introduction create an immune system "trained" on the wrong antigens (through damaged barriers) in the wrong context (absence of helminth/bacterial education). AD becomes the visible manifestation of this fundamental immune miseducation, setting the trajectory for chronic type 2 diseases.
- Affects 15-30% of children in industrialised countries; 2-10% of adults (lower adult prevalence reflects natural remission in 60-70% of cases by adolescence)
- 60% of moderate-to-severe AD patients carry FLG loss-of-function mutations (heterozygous or homozygous)
- First manifestation appears typically 3-6 months of age; 60% develop AD by age 1 year, 85% by age 5
- Over 90% of AD skin lesions colonised by S. aureus (vs. 5% colonisation in healthy individuals)
- IL-31 is the primary pruritogenic cytokine in AD; anti-IL-31 biologics (nemolizumab) reduce itch by >50%
- AD increases food allergy risk 6-fold; peanut allergy risk 11-fold in severe AD
- 50% of AD patients develop asthma ("atopic march" progression); risk higher with earlier AD onset and filaggrin mutations
- Elevated total IgE (>200 IU/mL) found in 80% of AD patients; correlates with disease severity
- Vitamin D deficiency (<20 ng/mL) present in >60% of AD patients; supplementation improves SCORAD by 6-10 points
- Skin pH in AD elevated to 6.0-7.0 (vs. normal 4.5-5.5); increased protease activity degrades barrier proteins
- TEWL in AD lesions 2-3 times normal; indicates severe barrier compromise
- Zinc deficiency common in AD (serum zinc <70 ΞΌg/dL in 30-40%); impairs wound healing and immune function
- Early peanut introduction (4-6 months) reduces peanut allergy by 81% in high-risk AD infants (LEAP trial)
- filaggrin β loss-of-function mutations are the strongest genetic risk factor for AD; filaggrin breakdown products constitute natural moisturising factors essential for barrier integrity
- barrier dysfunction β AD is fundamentally a disease of epithelial barrier failure; skin barrier defect allows inappropriate allergen entry establishing systemic immune dysregulation
- type 2 inflammation β AD is the prototypical type 2 inflammatory disease; driven by Th2 cells, ILC2s, IL-4, IL-13, and eosinophils creating allergic immune environment
- Th2 cells β produce IL-4, IL-13, IL-31 that drive AD pathology; Th2 dominance suppresses Th1 responses and antimicrobial defenses
- IL-4 β suppresses filaggrin transcription via STAT6, perpetuating barrier dysfunction; drives IgE class switching in B cells amplifying allergic sensitisation
- IL-13 β inhibits keratinocyte differentiation and ceramide synthesis; synergises with IL-4 to suppress barrier proteins and promote type 2 inflammation
- IL-31 β binds IL-31RA on sensory neurons causing intense pruritus; produced by Th2 cells and mast cells; primary target for anti-itch biologics
- atopic march β AD is typically the first step; establishes type 2 immune memory that manifests as food allergies, asthma, allergic rhinitis in sequential progression
- food allergies β risk increased 6-fold in AD infants; cutaneous allergen exposure through damaged barrier drives food sensitisation (dual allergen exposure hypothesis)
- asthma β develops in 50% of AD patients; shared type 2 inflammatory mechanisms; filaggrin mutations increase risk for both conditions
- allergic rhinitis β final manifestation of atopic march in 70% of AD patients; shared Th2 cytokine profile and IgE-mediated mechanisms
- IgE β elevated in 80% of AD patients reflecting systemic allergic sensitisation; total IgE >200 IU/mL typical; allergen-specific IgE identifies triggers
- Staphylococcus aureus β colonises >90% of AD skin producing superantigens and Ξ±-toxin; drives inflammation and barrier destruction; biofilms resist antimicrobials
- skin microbiome β profoundly disrupted in AD with loss of commensal diversity (S. epidermidis, Cutibacterium); S. aureus dominance perpetuates inflammation
- gut microbiome β dysbiosis in infancy increases AD risk via gut-skin axis; reduced Bifidobacteria and increased Enterobacteriaceae associated with AD development
- L-histidine β rate-limiting amino acid for filaggrin synthesis; supplementation 1-2g/day supports barrier repair; histidine depletion impairs filaggrin production
- vitamin D β deficiency worsens AD severity and increases infection risk; optimises antimicrobial peptide production; target 40-60 ng/mL for therapeutic effect
- oral tolerance β healthy oral allergen exposure promotes immune tolerance via gut GALT; disrupted in AD due to gut barrier dysfunction and cutaneous sensitisation
- TSLP β thymic stromal lymphopoietin released by damaged keratinocytes; potent driver of Th2 differentiation and type 2 inflammation in AD pathogenesis
- eosinophils β recruited to AD skin by IL-5; degranulate releasing toxic proteins and pro-inflammatory mediators; eosinophil count >500/ΞΌL indicates active type 2 inflammation
- Treg cells β regulatory T cells reduced or dysfunctional in AD; impaired immune regulation allows unchecked Th2 responses; SCFA production supports Treg function
- antimicrobial peptides β LL-37 and Ξ²-defensins suppressed by IL-4/IL-13 in AD; deficiency permits S. aureus colonisation and recurrent infections
- leaky gut β often concurrent with AD; gut barrier dysfunction allows allergen/endotoxin translocation amplifying systemic type 2 inflammation via gut-skin axis
- omega-3 fatty acids β EPA/DHA supplementation shifts eicosanoid production from inflammatory PGE2/LTB4 to anti-inflammatory resolvins; improves AD severity scores
- zinc β deficiency common in AD (30-40%); essential for barrier repair, Th1 function, and wound healing; supplementation 25-50mg/day supports skin integrity